Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201552 | 0.78 | CYP19A1 (0.80) | CYP19A1HTR1A | |
| SCHEMBL155247 | 0.73 | CYP19A1 (1.00) | CYP19A1CYP1A1MAPTL3MBTL1 | |
| SCHEMBL4564456 | 0.72 | CYP19A1 (0.69) | CYP19A1HTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7263772 | 0.72 | CYP19A1 (0.96) | CYP19A1CYP1A1MAPTL3MBTL1 | |
| SCHEMBL29820095 | 0.72 | CYP19A1 (0.69) | CYP19A1 | |
| SCHEMBL6881194 | 0.70 | CYP19A1 (0.67) | CYP19A1HTR1A | |
| SCHEMBL16129814 | 0.70 | CYP19A1 (0.67) | CYP19A1HTR1A | |
| SCHEMBL10194241 | 0.70 | CYP19A1 (0.67) | CYP19A1HTR1AMEN1ALDH1A1MAPT | |
| SCHEMBL3153071 | 0.70 | CYP19A1 (0.67) | CYP19A1HTR1AALDH1A1MAPT | |
| SCHEMBL29820189 | 0.70 | CYP19A1 (0.67) | CYP19A1HTR1AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | CYP19A1 598/4885TAAR1 502/4885HTR1A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.